SYDNEY--(

悉尼--(

BUSINESS WIRE

商业热线

)--Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for

)--全球领先的全方位服务临床合同研究组织（CRO）Novotech发布了一份综合报告，分析了全球临床试验和药物开发前景

Triple-Negative Breast Cancer (TNBC)

三阴性乳腺癌（TNBC）

. The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments.

该报告强调了治疗策略，区域临床试验活动以及推动创新TNBC治疗的不断发展的生物标志物方面的重大进展。

A Highly Aggressive Breast Cancer Subtype

高度侵袭性乳腺癌亚型

TNBC, representing

TNBC，代表

10-15%

10-15%

of breast cancer cases worldwide, is characterized by the absence of key receptors (ER, PR, HER2), limiting the efficacy of targeted hormonal therapies. Despite advances, TNBC remains associated with

在世界范围内的乳腺癌病例中，其特征是缺乏关键受体（ER，PR，HER2），从而限制了靶向激素疗法的疗效。尽管取得了进展，TNBC仍然与

poor survival rates

生存率低

, with metastatic cases exhibiting five-year survival of under

，转移病例的五年生存率低于

12%

12%

.

.

Global Clinical Trial Insights

全球临床试验见解

From 2019 to 2024, over

2019年至2024年

1,500 clinical trials

1500项临床试验

for TNBC were initiated globally, highlighting a robust commitment to improving patient outcomes. Key findings include:

TNBC在全球范围内启动，突出了对改善患者预后的坚定承诺。主要调查结果包括：

Regional Leadership

区域领导力

: North America led TNBC trials (39%), followed closely by Asia-Pacific (33%), Europe (21%), and ROW (7%). The

：北美领先的TNBC试验（39%），其次是亚太地区（33%），欧洲（21%）和世界其他地区（7%）。The

United States

美国

accounted for

占比

83%

83%

of North America’s trials, while

北美的审判

China

中国

and

和

Australia

澳大利亚

emerged as regional leaders in Asia-Pacific.

成为亚太地区的领导者。

Biomarker-Driven Research

生物标志物驱动的研究

: Novel biomarkers such as

：新型生物标志物，例如

BRCA1/2 mutations, PD-L1 expression

BRCA1/2突变，PD-L1表达

, and

，以及

FGFR amplifications

FGFR扩增

are increasingly targeted to drive precision therapies.

越来越多的目标是推动精准治疗。

Trial Density & Recruitment

试用密度和招聘

: Asia-Pacific’s lower trial density and faster recruitment rates provide unique opportunities for TNBC-focused research, supported by a large and diverse patient pool.

：亚太地区较低的试验密度和较快的招募率为TNBC重点研究提供了独特的机会，并得到了大量多样化患者的支持。

Innovation in Therapeutics

治疗学创新

TNBC drug development reflects a multi-stage pipeline, with

TNBC药物开发反映了一个多阶段的流程

78 Phase I, 97 Phase II

78一期，97二期

, and

，以及

12 Phase III

12第三阶段

trials underway. The evolution of therapeutic strategies includes:

试验正在进行中。治疗策略的演变包括：

Targeted Therapies

靶向治疗

: PARP inhibitors, immune checkpoint inhibitors (ICIs), and novel antibody-drug conjugates (ADCs) are transforming treatment paradigms.

：PARP抑制剂，免疫检查点抑制剂（ICI）和新型抗体-药物偶联物（ADC）正在改变治疗模式。

Combination Approaches

组合方法

: Synergistic therapies combining immunotherapy, chemotherapy, and targeted agents are enhancing efficacy.

：结合免疫疗法，化疗和靶向药物的协同疗法正在提高疗效。

Significant Opportunity in Asia-Pacific

亚太地区的重大机遇

The Asia-Pacific region, with its genetic diversity and unmet clinical needs, remains a focal point for TNBC trials. Novotech’s presence in key Asia-Pacific markets provides a strategic advantage in accelerating clinical research for novel

亚太地区具有遗传多样性和未满足的临床需求，仍然是TNBC试验的焦点。Novotech在亚太地区主要市场的存在为加速新型药物的临床研究提供了战略优势

TNBC therapies

TNBC 疗法

.

.

About Novotech

关于Novotech

Novotech-CRO.com

Novotech-CRO.com 网站

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.

Novotech成立于1997年，是一家全球全方位服务的临床合同研究组织（CRO），专注于与生物技术和中小型公司合作，以加速各个阶段先进和新颖疗法的开发。

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006..

Novotech因其行业领先的贡献而备受赞誉，它获得了许多久负盛名的奖项，包括临床试验管理和全球运营领域的Fierce CRO 2024卓越奖、Frost＆Sullivan 2024全球生物技术年度CRO奖、Clinical Trials Arena 2024商业扩张、创新和营销领域的卓越奖、2024年雇主选择奖、2024年美国工作大好地方奖、2024年布兰登·霍尔金奖、2023年CRO领导力奖、2023年亚太细胞与基因治疗临床试验卓越奖、2006年以来的亚太合同研究组织年度公司奖。。

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice..

该公司提供一整套服务，包括实验室、一期设施、药物开发咨询、监管专业知识，并拥有5000多个临床项目的经验，包括一期至四期临床试验和生物等效性研究。Novotech在全球34个办公地点设有办事处，拥有3000多名专业人员组成的专门团队，是值得信赖的端到端战略合作伙伴。。

For more information or to speak to an expert team member visit

欲了解更多信息或与专家团队成员交谈，请访问

www.Novotech-CRO.com

www.Novotech-CRO.com